Timely Evaluation for Surgical Treatment of Aortic Valve Disease

Time is of the essence...
The pathology of aortic valve disease (AVD) typically develops over many years, and symptoms may not appear until the condition is severe. When symptoms develop, the rates of morbidity and mortality among patients are high.¹

If AVD is left untreated or medically managed...

For aortic regurgitation (AR)²,³

- 25% of patients who have asymptomatic moderate-to-severe AR will die within 5 years after diagnosis, and 50% will die within 10 years.
- 25% of patients with symptomatic (NYHA class III/IV) moderately severe or severe AR will die within 1 year of diagnosis.

For aortic stenosis (AS)⁴

- 56% of patients who have moderate AS and 67% of those who have severe AS will die within 5 years of diagnosis.
- 21% of patients who have moderate AS and 29% of those who have severe AS will die within 1 year of diagnosis.

2020 ACC/AHA Guideline recommendations for treatment of AVD⁵

- **Aortic regurgitation:** Surgical aortic valve replacement (SAVR) is recommended for the treatment of symptomatic severe aortic regurgitation and asymptomatic chronic severe AR with left ventricular (LV) systolic dysfunction.

- **Aortic stenosis:** SAVR is recommended for patients who have symptomatic or asymptomatic severe AS with LV dysfunction and are <65 years of age or have a life expectancy >20 years.

Among aortic valve replacement options, SAVR is the only guideline-directed treatment indicated to treat both AS and AR.
Timely evaluation can lead to timely intervention for patients...

The current convention for treating asymptomatic severe AVD is to provide treatment once symptoms develop. However, advances in surgical techniques and aortic valve prostheses may help change this.  

**Referral for SAVR**

SAVR treatment is a class 1 indication (ie, is strongly recommended) for patients who have asymptomatic severe AR with LV systolic dysfunction and for patients who have asymptomatic severe AS. Guidelines suggest that postoperative outcomes are better when surgery is performed early or before the onset of symptoms.  

For additional information on surgical aortic valves:

- [www.yourtissuevalve.com](http://www.yourtissuevalve.com)
- [www.edwards.com/inspiris](http://www.edwards.com/inspiris)
- [www.edwards.com/inspiring](http://www.edwards.com/inspiring)

**Important Safety Information:**

**INSPIRIS RESILIA Aortic Valve**

**Indications:** For use in replacement of native or prosthetic aortic heart valves.

**Contraindications:** There are no known contraindications with the use of the INSPIRIS RESILIA aortic valve.

**Complications and Side Effects:** Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation, permanent disability, and death.

**Warnings:** DO NOT ADJUST THE VALVE DIAMETER BY EXPANDING THE BAND PRIOR TO OR DURING IMPLANTATION OF THE SURGICAL VALVE. The expandable band is not designed to allow for compression or expansion during implantation of the surgical valve. This will cause damage to the valve and may result in aortic incompetence. DO NOT PERFORM STAND-ALONE BALLOON AORTIC VALVULOPLASTY PROCEDURES ON THIS VALVE FOR THE SIZES 19-25 mm as this may expand the valve causing aortic incompetence, coronary embolism or annular rupture. Valve-in-valve sizing in the INSPIRIS valve has only been tested with specific Edwards transcatheter heart valves. Use of other transcatheter valves may result in embolization of transcatheter devices anchored within or result in annular rupture.

**CAUTION:** Federal (USA) law restricts these devices to sale by or on the order of a physician. See instructions for use for full prescribing information.

**References**


Edwards Lifesciences, the stylized E logo, INSPIRIS, INSPIRIS RESILIA, and RESILIA are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--US-6634 v1.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com